NDA 206255 approval letter – Soolantra (ivermectin) Cream, 1%, for rosacea (2014)

Government Record · U.S. Food and Drug Administration, Center for Drug Evaluation and Research · December 19, 2014

U.S. Food et al., 2014-12-19: FDA approval letter for the 1% ivermectin cream for rosacea, addressed to Galderma.

This new drug application provides for the use of Soolantra (ivermectin) Cream, 1 % for treatment of inflammatory lesions of rosacea.

1

U.S. Food et al., 2014-12-19: FDA approval letter for the 1% ivermectin cream for rosacea, addressed to Galderma. C6 Soolantra. Record fields: NDA 206255, applicant 'Galderma Research and Development, LLC', Fort Worth TX; application received December 20, 2013, submitted under section 505(b)(2); approved 2014-12-19. The 505(b)(2) route means the application relied in part on the Agency's finding of safety and/or effectiveness for a listed drug rather than on all new studies. Study type: regulatory record.